drugset / Trial / NCT02950870
Efficacy Study to Evaluate the Effect of New Antiviral Drugs on HCV Infection.
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determinate the AMH levels before and after antiviral therapy with Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir in comparison with age-matched HCV-positive women not undergoing antiviral treatment.
Timeline
- Start
- 2016-12
- Primary completion
- 2017-12
- Completion
- 2019-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ribavirin | Small molecule | — | — |
| Subject | Ritonavir | Other / unclassified | 100 mg | — |
| Subject | dasabuvir | Small molecule | 500 mg | — |
| Subject | ombitasvir | Small molecule | 25 mg | — |
| Subject | paritaprevir | Small molecule | 150 mg | — |